Cu-SAR-BisPSMA在发现前列腺癌复发、改变44%的病人的治疗方式方面业绩超过标准成像。 Cu-SAR-bisPSMA outperformed standard imaging in detecting prostate cancer recurrence, changing treatment for 44% of patients.

在2026年欧洲航空联盟大会上介绍的第二阶段试验发现,在50名前列腺切除后PSA水平较低的男子中,清晰治疗学的Cu-SAR-BisPSMA成像检测到的前列腺癌症复发率大大高于Ga-PSMA-11标准病例。 A Phase II trial presented at the 2026 EAU Congress found Clarity Therapeutics’ Cu-SAR-bisPSMA imaging detected significantly more prostate cancer recurrences than standard Ga-PSMA-11 in 50 men with low PSA levels after prostatectomy. Cu-SAR-BisPSMA发现,63人受到损伤,24人受到损伤,前列腺福萨和淋巴结的检测有所改进,导致44%的病人改变了治疗计划,主要是从监测转向定向放射疗法。 Cu-SAR-bisPSMA identified 63 lesions versus 24, improved detection in the prostate fossa and lymph nodes, and led to a change in treatment plans for 44% of patients, primarily shifting from surveillance to targeted radiotherapy. 结果支持美国FDA未来的市场授权申请. Results support a future U.S. FDA market authorization application.